Shoreline draws $140M to advance cell therapy pipeline

With a new $140 million series B round nearly doubling the amount it had raised previously, Shoreline will have ample runway to test its iPS cell-derived NK cell therapies in the clinic, both on its own and with high-profile partners.

Co-founding Chairman and CEO Kleanthis Xanthopoulos told BioCentury that the broad vision of Shoreline Biosciences Inc. is to bring off-the-shelf, allogeneic cell therapies to as many patients as possible by making them available through community hospital settings, rather than via specialized centers as autologous CAR T therapies are delivered...